Burning Rock
Burning Rock Details Plans for Cancer Monitoring Assay, Adds New Data Supporting Early Detection
Premium
Both the MRD test, BR Prophet, and a six-cancer screening assay, BR Predict, are slated for launch in China next year, initially for contracted hospital customers.
360Dx Index Maintains Steady Ascent, Increasing 3 Percent in August
Of the 29 companies in the index, 18 saw increases in their stock prices, while 11 saw declines.
Burning Rock Q2 Revenues up 19 Percent
The company highlighted growth in its hospital testing business, which increased 47 percent with 34 contracted partner hospitals now on the books.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
360Dx Index Continues Growth in July, Increasing 5 Percent
Of the 29 companies in the index, 16 saw increases in their stock prices, while 13 saw declines.
May 26, 2021
May 25, 2021
Burning Rock Q1 Revenues Rise 58 Percent
Mar 11, 2021
Burning Rock Q4 Revenues Rise 50 Percent
Nov 20, 2020